Incyte’s Opzelura gets MHRA authorisation
Therapy involves the treatment of non-segmental vitiligo among adults and adolescents
Read Moreby John Pinching | Jul 7, 2023 | News | 0
Therapy involves the treatment of non-segmental vitiligo among adults and adolescents
Read Moreby Lucy Parsons | Apr 22, 2021 | News | 0
Oral JAK inhibitor improved hair regrowth across both dosing groups
Read Moreby Selina McKee | Apr 9, 2021 | News | 0
The drug failed to significantly reduce progression to ventilation or death in patients hospitalised with COVID-19
Read Moreby Lucy Parsons | Mar 30, 2021 | News | 0
Kinase inhibitor authorised to treat advanced bile duct cancer patients with a FGFR2 fusion or rearrangement
Read Moreby Lucy Parsons | Nov 3, 2020 | News | 0
Data presented at virtual European Academy of Dermatology and Venereology congress
Read Moreby Selina McKee | Apr 20, 2020 | News | 0
Incyte’s Pemazyre can now be used to treat the bile duct cancer. The firm has also launched a global COVID-19 trial
Read Moreby Anna Smith | Aug 27, 2019 | News | 0
Both the 4mg and 2mg dosages met the trials’ primary endpoint in BREEZE-AD1 and BREEZE-AD2.
Read Moreby Selina McKee | Jun 4, 2018 | News | 0
As expected, US regulators have approved the lower dose of Eli Lilly/Incyte’s once-daily JAK inhibitor Olumiant as treatment for rheumatoid arthritis (RA).
Read Moreby Selina McKee | Apr 24, 2018 | News | 0
US regulatory advisors are backing approval of the lower dose form of Eli Lilly and Incyte’s once-daily JAK inhibitor baricitinib as treatment for rheumatoid arthritis (RA).
Read Moreby Selina McKee | Apr 9, 2018 | News | 0
A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma.
Read Moreby Selina McKee | Nov 1, 2017 | News | 0
AstraZeneca and MedImmune have expanded their clinical collaboration with Incyte to carry out a late-stage trial assessing an experimental combination therapy for lung cancer.
Read Moreby Selina McKee | May 2, 2017 | News | 0
Chronic Myeloid Leukaemia (CML) patients in England who are resistant or intolerant to second generation tyrosine kinase inhibitor (TKI) therapies are on the brink of getting full-access to Incyte’s Iclusig on the NHS following a nod from NICE.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
